Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

The role of mesalamine in the treatment of ulcerative colitis

Authors Raffi Karagozian, Robert Burakoff

Published 15 November 2007 Volume 2007:3(5) Pages 893—903

Raffi Karagozian, Robert Burakoff

Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Abstract: Ulcerative colitis (UC) is a chronic inflammatory condition of unclear etiology affecting the large bowel, most commonly the rectum and extending proximally in a continuous fashion. The overall principle in the pathophysiolgy of ulcerative colitis is the dysregulation of the normal immune system against an antigenic trigger leading to a prolonged mucosal inflammatory response. The diagnosing of UC is made by combining the clinical picture, tissue biopsy with the endoscopic appearance of mucosal ulceration, friable, edematous, erythematous granular appearing mucus. The approach to therapy of UC has been dependent on severity of symptoms with frontline therapy being salicylate based sulfasalazine. Newer formulations of salicylates based drugs with fewer side-effects have been developed. These are free of the sulphur component and are composed of 5-ASA, without the sulfapyridine carrier molecule. Mesalamine is one of these 5-ASA based agents that are currently available and indicated for treatment of UC. In mild/moderate active disease mesalamine has response rates between 40%–70% and remission rates of 15%–20%. Considering that the efficacy of 5-ASA is dose dependent, 4.8 g/day and 2.4 g/day have been shown to be the optimal dosages for mild-moderate distal active disease and for maintenance therapy, respectively. Patients with moderately active ulcerative colitis treated with 4.8 g/d of mesalamine are significantly more likely to achieve overall improvement at week 6 compared to patients treated with 2.4 g/d. In the setting of left-sided distal colitis (proctitis), topical (rectal) formulations have been found to be superior to oral aminosalicylates at inducing remission. Mesalamine has been shown to be safe in short term use with a dose-response efficacy without dose-related toxicity.

Keywords: ulcerative colitis (UC), mesalamine, 5-ASA therapy, inflammatory bowel disease, remission

Download Article [PDF] 

Readers of this article also read:

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

Alexander Rapidis, Nicholas Sarlis, Jean-Louis Lefebvre, Merrill Kies

Therapeutics and Clinical Risk Management 2008, 4:865-886

Published Date: 10 October 2008

Editorial  ||FREE PAPER||

Garry M Walsh

Therapeutics and Clinical Risk Management 2008, 4:0-0

Published Date: 6 June 2008

Towards a new standard of perioperative fluid management

Conor J Shields

Therapeutics and Clinical Risk Management 2008, 4:569-571

Published Date: 11 April 2008

Update on local anesthetics: focus on levobupivacaine

Crina L Burlacu, Donal J Buggy

Therapeutics and Clinical Risk Management 2008, 4:381-392

Published Date: 11 April 2008

A critical analysis of barriers to the clinical implementation of pharmacogenomics

Ross A McKinnon, Michael B Ward, Michael J Sorich

Therapeutics and Clinical Risk Management 2007, 3:751-759

Published Date: 15 November 2007

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

Andrew J Armstrong, Daniel J George

Therapeutics and Clinical Risk Management 2007, 3:877-883

Published Date: 15 November 2007

Targeting CD22 as a strategy for treating systemic autoimmune diseases

Thomas Dörner, David M Goldenberg

Therapeutics and Clinical Risk Management 2007, 3:953-959

Published Date: 15 November 2007

A review of the use of adapalene for the treatment of acne vulgaris

Suleyman Piskin, Erol Uzunali

Therapeutics and Clinical Risk Management 2007, 3:621-624

Published Date: 15 September 2007